恩替卡韦分散片治疗慢性乙型肝炎的早期临床观察

Early clinical observation of entecavir dispersible tablets on the treatment of chronic hepatitis B

目的针对恩替卡韦分散片治疗慢性乙型肝炎的早期临床疗效观察。方法选取120例慢性乙型肝炎患者,将其随机分为两组各60例,对照组给予常规保肝治疗;实验组在此基础上给予恩替卡韦进行抗病毒治疗。结果治疗前,两组比较,差异无统计学意义(P>0.05);在治疗8、12、24、48周后,TB、ALT、PT组间比较,治疗组优于对照组差异,均有统计学意义(P<0.05);ALB治疗后各个时间段比较,组间差异无统计学意义(P>0.05)。治疗组患者治疗后12、24、48周时HBVDNA和HBeAg转阴患者例数分别为17例(28.3%)、39例(65.0%)、58例(96.7%);对照组患者治疗后12、24、48周时HBVDNA和HBeAg转阴患者例数分别为5例(8.3%)、11例(18.3%)、43例(71.7%)。治疗后24、48周时HBVDNA、HBeAg转阴率比较,差异有统计学意义(P<0.05)。结论恩替卡韦治疗慢性乙型肝炎起效快、安全性高及副作用小,值得广泛应用。

Objective Entecavir dispersible tablets for chronic hepatitis B early clinical efficacy observed.Methods Selected 120 cases of chronic hepatitis B patients were randomly divided into two groups,60 cases in the control group treated with conventional liver treatment;in the experimental group on this basis,antiviral treatment with entecavir.Results Compared every indicators of two groups before treatment,the difference was not statistically significant （P0.05）;Treatment of 8,12,24,48 weeks,the TB,ALT,PT of treatment group were better than the control group,and the difference were statistically significant （P 0.05）;ALB comparison between each period after treatment,there were no statistically significant differences between the two groups （P 0.05）.12,24 and 48 weeks after treatment in patients with therapy,HBVDNA and HBeAg negative conversion cases were 17 cases （28.3%）,39 cases （65%）,58 cases （96.7%） respectively;and those corresponding indicators of control group were 5 cases （8.3%）,11 cases （18.3%）,43 cases （71.7%） respectively.Compared the HBVDNA,HBeAg negative conversion rate at 24 and 48 weeks after treatment,there were statistically significant differences （P 0.05）.Conclusion Entecavir Tablets for chronic hepatitis B with rapid onset of high safety and side effects is small,it was worth the extensive application.